生长抑素对比奥曲肽预防术后胰瘘:PREFIPS随机临床试验:法国007-ACHBT研究
PREFIPS多中心随机对照开放研究纳入651例胰十二指肠切除术或远端胰腺切除术患者,比较连续静脉输注生长抑素7天与皮下注射奥曲肽100 μg每8小时1次共7天对90天B/C级术后胰瘘的预防效果,结果两组B/C级胰瘘发生率无统计学差异(生长抑素组24.1% vs 奥曲肽组22.9%,P=0.73)。
要点
- 生长抑素连续静脉输注与奥曲肽皮下注射预防B/C级术后胰瘘发生率无统计学差异。
- 总体B/C级胰瘘发生率为23.5%(153/651),生长抑素组24.1%,奥曲肽组22.9%。
- 按方案分析和校正分层变量后,两组差异仍无统计学意义。
核心结论
- 连续静脉输注生长抑素与皮下注射奥曲肽在预防胰腺切除术后B/C级胰瘘方面无统计学差异。
研究设计与样本
- 多中心随机对照开放研究,纳入拟行胰十二指肠切除术或远端胰腺切除术的患者,按手术方式和主胰管是否扩张(>4 mm)分层,比较生长抑素连续静脉输注7天与奥曲肽100 μg每8小时1次皮下注射7天,主要终点为90天B/C级术后胰瘘发生率,采用意向性分析。
主要发现
- 763例符合条件患者中651例随机分组:奥曲肽组327例,生长抑素组324例,分层标准(手术类型和主胰管扩张)具有可比性。
- 大多数患者行胰十二指肠切除术(480例,73.8%),胰腺质地软/正常(367例,63.2%),主胰管未扩张(472例,72.5%),最常见原因为胰腺腺癌(311例,47.8%)。
- 几乎全部患者留置腹腔引流(621例,96.1%),121例(19.5%)带引流管出院(中位住院时间16天)。
- 共153例患者(23.5%)发生B/C级术后胰瘘,两组无差异:生长抑素组24.1%,奥曲肽组22.9%(χ²检验,P=0.73,意向性分析)。
- 校正分层变量后及按方案分析中,无统计学显著差异的结果持续存在。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Pharmacological prevention of postoperative pancreatic fistula (POPF) after pancreatectomy is open to debate. The present study compares clinically significant POPF rates in patients randomized between somatostatin versus octreotide as prophylactic treatment. METHODS: Multicentric randomized controlled open study in patient's candidate for pancreaticoduodenectomy (PD) or distal pancreatectomy (DP) comparing somatostatin continuous intravenous infusion for 7 days versus octreotid 100 μg, every 8 hours subcutaneous injection for 7 days, stratified by procedure (PD vs DP) and size of the main pancreatic duct (>4 mm) on grade B/C POPF rates at 90 days based on an intention-to-treat analysis. RESULTS: Of 763 eligible patients, 651 were randomized: 327 in the octreotide arm and 324 in the somatostatin arm, with comparable the stratification criteria - type of surgery and main pancreatic duct dilatation. Most patients had PD (n=480; 73.8%), on soft/normal pancreas (n=367; 63.2%) with a nondilated main pancreatic duct (n=472; 72.5%), most often for pancreatic adenocarcinoma (n=311; 47.8%). Almost all patients had abdominal drainage (n=621; 96.1%) and 121 (19.5%) left the hospital with the drain in place (median length of stay=16 days). A total of 153 patients (23.5%) developed a grade B/C POPF with no difference between both groups: 24.1%: somatostatin arm and 22.9%: octreotide arm (χ 2 test, P =0.73, ITT analysis). Absence of statistically significant difference persisted after adjustment for stratification variables and in per-protocol analysis. CONCLUSION: Continuous intravenous somatostatin is not statistically different from subcutaneous octreotide in the prevention of grade B/C POPF after pancreatectomy. FINDINGS: In the PREFIPS Randomized Clinical Trial including 651 patients, a total of 153 patients (23.5%) developed a grade B/C POPF with no significant difference between both groups: 24.1%: somatostatin arm and 22.9%: octreotide arm (χ 2 test, P =0.73, ITT analysis). Absence of statistically significant difference persisted after adjustment for stratification variables and in per-protocol analysis.
引用
- Gaujoux S, Regimbeau JM, Piessen G, et al. Somatostatin Versus Octreotide for Prevention of Postoperative Pancreatic Fistula: The PREFIPS Randomized Clinical Trial: A FRENCH 007-ACHBT Study. Ann Surg. 2024. PMID: 38662619. doi:10.1097/SLA.0000000000006313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。